Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies

Sanne J. M. Hoefnagel, Willem J. Koemans, Hina N. Khan, Jan Koster, Sybren L. Meijer, Jolanda M. van Dieren, Liudmila L. Kodach, Johanna W. van Sandick, Silvia Calpe, Carmen M. del Sancho-Serra, Ana C. P. Correia, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz, Maarten C. C. M. Hulshof, Sandro Mattioli, Manon C. W. Spaander, Kausilia K. Krishnadath

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

Esophageal adenocarcinoma (EAC) is a highly aggressive cancer and its response to chemo- and radiotherapy is unpredictable. EACs are highly heterogeneous at the molecular level. The aim of this study was to perform gene expression analysis of EACs to identify distinct molecular subgroups and to investigate expression signatures in relation to treatment response. In this prospective observational study, RNA sequencing was performed on pre-treatment endoscopic EAC biopsies from a discovery cohort included between 2012 and 2017 in one Dutch Academic Center. Four additional cohorts were analyzed for validation purposes. Unsupervised clustering was performed on 107 patients to identify biological EAC subgroups. Specific cell signaling profiles were identified and evaluated with respect to predicting response to neo-adjuvant chemo(radio)therapy. We identified and validated three distinct biological EAC subgroups, characterized by (1) p38 MAPK/Toll-like receptor signaling; (2) activated immune system; and (3) impaired cell adhesion. Subgroup 1 was associated with poor response to chemo-radiotherapy. Moreover, an immune signature with activated T-cell signaling, and increased number of activated CD4 T memory cells, neutrophils and dendritic cells, and decreased M1 and M2 macrophages and plasma cells, was associated with complete histopathological response. This study provides a novel molecular classification for EACs. EAC subgroup 1 proved to be more therapy-resistant, while immune signaling was increased in patients with complete response to chemo-radiotherapy. Our findings give insight into the biology of EACs and in cellular signaling mechanisms underlying response to neo-adjuvant treatment. Future implementation of this classification will improve patient stratification and enhance the development of targeted therapies.
Original languageEnglish
Article number4498
JournalCancers
Volume14
Issue number18
DOIs
Publication statusPublished - 1 Sept 2022

Keywords

  • RNA sequencing
  • esophageal adenocarcinoma
  • predicting response to therapy
  • subgroups

Cite this